checkAd
    Startseite > Aktien > Lexicon Pharmaceuticals > Nachrichten
    Lexicon Pharmaceuticals
    Aktie
    ISIN: US5288723027 WKN: A14SSK SYM: LXRX Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,8200
     
    USD
    -0,55 %
    -0,0100 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    14.06.24
    1,8200
     
    USD
    19.700 STK
    Briefkurs
    14.06.24
    1,8300
     
    USD
    7.000 STK

    Lexicon Pharmaceuticals Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
    14.06.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
    29.05.24 · globenewswire · Lexicon Pharmaceuticals
    New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
    14.05.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
    09.05.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    02.05.24 · globenewswire · Lexicon Pharmaceuticals
    Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
    29.04.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
    29.04.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals to Host 2024 Investor Day
    18.04.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire · Lexicon Pharmaceuticals
    Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
    25.03.24 · globenewswire · Lexicon Pharmaceuticals
    New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
    12.03.24 · globenewswire · Lexicon Pharmaceuticals
    Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
    11.03.24 · globenewswire · Lexicon Pharmaceuticals